Key takeaways
- A CRM full of leads with no ranking means reps just work whoever made noise that week.
- Rank on whether you can win the account, whether the right buyer is there, and whether anything's happening now.
Most prioritization problems are not a data problem, they are a ranking problem. A CRM full of leads with no ranking means reps just work whoever made noise that week, whether or not that company was ever going to buy.
The fix is not more data. It is ranking every account on three questions, in order: can you win it, is the right buyer there, and is anything happening now.
Can you win the account?
You can win an account if it looks like the companies you already sell to and win. For a CRO, CDMO, or life science tools and services vendor, that usually comes down to a few concrete things: therapeutic area or modality overlap, development stage (a CDMO selling process development work cares a lot about preclinical versus Phase 2 versus commercial-stage), company size, and how closely the account resembles your best existing customers. See building an ICP as a CRO or CDMO for how to define this.
It comes first because signals are loud and fit is quiet. A funding round or a booth at a major conference is easy to get excited about. Whether that company is even in your market takes more discipline to check, and that check is what keeps your list from filling up with noise.
Is the right buyer there?
The right buyer is there when someone at the company matches your buyer profile: the right function (the team that owns the problem you solve) at a seniority that can influence or approve a purchase. A good-fit company is still not workable without that person in place. This is where life science differs from generic B2B advice. Titles vary widely between a 20-person biotech and a commercial-stage pharma, and a Director at a small biotech can carry the authority of a VP at a larger one, so judge the role, not the job-title string.
When a company is a good fit but you have not found the right person yet, the next step is to go find them, not to drop the account.
Is anything happening now?
Something is happening now when a recent change makes a conversation more likely to land: new budget, a new need, a new decision-maker, or a shift in strategy. For the accounts that already clear both fit gates above, that is the timing question that sequences your good-fit list, not a way to pull an account onto the list that never belonged there. See which buying signals actually matter in biotech and pharma and timing outreach with readiness signals for the detail.
What to do with each account
Answer those three questions and every account lands in one of four buckets, each with a different next step, instead of one flat "priority" number that hides what is actually going on:
Good company fit + good buyer fit + an active signal
The account passed both fit gates and something just happened. This is where outreach effort should go this week.
Good company fit + good buyer fit, no active signal
A real account worth keeping on the list. Do not manufacture urgency here; wait for a signal instead of cold-blasting on a schedule.
Good company fit, no matching buyer identified yet
The company is worth working, but nobody has found the right person. The next step is research, not an email.
Weak company fit
Regardless of how loud the signal is, this account does not resemble who you sell to. No amount of readiness should pull it back onto the working list.
Common mistakes
- Treating every good-fit account the same. A great-fit account with no signal and a great-fit account with three signals stacked on top of each other are not the same priority, even though both cleared the fit bar.
- Scoring buyer fit on job title text alone. Life science titles are inconsistent across company size and structure; a title-matching rule misses good contacts and lets in irrelevant ones.
- Letting signals rescue bad-fit accounts. A funding round or a conference booth at a company outside your ICP is still not a lead, it is a data point about a company you were never going to sell to.
- Re-ranking the whole list by hand every week. Fit is stable and worth a periodic review; readiness needs continuous monitoring, because the events that drive it happen on their own schedule, not yours.
Putting it into practice
A simple starting model most teams can run without new tooling: maintain a company fit score and a buyer fit score for every account and contact, and only pull in signal data for accounts that clear both. From there, sort the qualified list by how recent and how strong the active signals are, and treat everything else as a monitored backlog rather than a queue to work through. The mechanics of scoring get easier to automate than to do by hand once your CRM has more than a few hundred contacts in it, which is the point at which most teams start looking for a system to do the ranking continuously instead of re-sorting a spreadsheet.